Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study-Reference-Cited by-同舟云学术

Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study

Published:2021-11-17 Issue:1 Volume:39 Page:488-503
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Xu Junyu,Zhang Yifei,Li Yiming,Zhao Xia,Zhou Weiwei,Loghin Corina,Tham Lai San,Cui Xuewei,Cui Yimin^ORCID,Wang Weiqing

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-021-01921-5.pdf

Reference26 articles.

1. Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab. 2020. https://doi.org/10.1016/j.molmet.2020.101102.

2. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85. https://doi.org/10.1016/s2213-8587(19)30249-9.

3. Diamant M, Nauck MA, Shaginian R, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care. 2014;37(10):2763–73. https://doi.org/10.2337/dc14-0876.

4. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111–24. https://doi.org/10.2337/dc21-S009.

5. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Injectable Dulaglutide 1.5 mg Among Type 2 Diabetes Patients in Clinics at King Saud Medical City, Riyadh, Saudi Arabia;Journal of Epidemiology and Global Health;2024-05-16

2. Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome;Pharmaceuticals;2024-04-19

3. A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects;Clinical and Translational Science;2024-04

4. Efficacy and Safety of Injectable Dulaglutide 1.5 mg among Type 2 Diabetes Patients in Clinics at King Saud Medical City, Riyadh, Saudi Arabia;2023-11-20

5. Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design;Biomedicines;2023-05-16